Singapore markets open in 31 minutes

PAVmed Inc. (PAVM)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.2775+0.0097 (+3.62%)
At close: 04:00PM EST
0.2702 -0.01 (-2.63%)
After hours: 05:32PM EST
Full screen
Trade prices are not sourced from all markets
Previous close0.2678
Open0.2720
Bid0.2661 x 1000
Ask0.2800 x 1800
Day's range0.2000 - 0.3095
52-week range0.2000 - 0.7190
Volume991,261
Avg. volume650,025
Market cap33.511M
Beta (5Y monthly)0.79
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
All
News
  • PR Newswire

    Lucid Diagnostics Strengthens and Expands Market Access and Direct Contracting Efforts

    Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), announced that the Company has strengthened and expanded its executive team with two industry veterans to support its critical market access and direct contracting efforts. Natalie S. Carfora joins Lucid as Vice President, Market Access, and James M. Fricchione as Vice President, Employe

  • PR Newswire

    PAVmed Provides Business Update and Third Quarter Financial Results

    PAVmed Inc. (NASDAQ: PAVM, PAVMZ) ("PAVmed" or the "Company"), a diversified commercial-stage medical technology company, operating in the medical device, diagnostics, and digital health sectors, today provided a business update for the Company and its subsidiaries, Lucid Diagnostics Inc. (NASDAQ: LUCD) ("Lucid") and Veris Health Inc. ("Veris"), and presented financial results for the Company for the three and nine months ended September 30, 2023.

  • PR Newswire

    Lucid Diagnostics Provides Business Update and Third Quarter Financial Results

    Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company, and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ) ( "PAVmed"), today provided a business update for the Company and presented financial results for the three and nine months ended September 30, 2023.